(RTTNews) - Rapport Therapeutics, Inc. (RAPP), a clinical-stage biotechnology company focused on central nervous system disorders, on Thursday, announced promising results from its Phase 1 PET and MAD ...
Draig Therapeutics Ltd. launched with a $140 million series A and an AMPA receptor modulator program that has completed phase I and will start a phase II trial in major depressive disorder later in ...
While the COVID pandemic has thankfully been over for some time now, there is still a considerable number of people in the world (about 400 million) suffering from long COVID. Long COVID is a chronic ...
The research, published June 4 in Nature Structural & Molecular Biology, identifies critical connections between activity of the epilepsy drug perampanel and the resulting movements of the AMPA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback